EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum -Exposed, Drug-Treated Kenyan Adults

Nathanial K Copeland iD, Lucas Otieno, June Doryne Otieno, Solomon Otieno, Salome Chira, Karen Ivinson, Irene Onyango, Ruth Wasuna, Hoseah Akala, Amos Onditi, Peter Sifuna, Ben Andagalu iD und 14 weitere

The Journal of Infectious Diseases · 15.09.2025 · 232 (3) · e372-e382

DOI: 10.1093/infdis/jiaf274 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.05.2025. Verfasst von Nathanial K Copeland und 25 weiteren Autor:innen. Beteiligte Einrichtung: Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya. Hauptthemen laut MEDLINE: Malaria, Falciparum, Plasmodium falciparum, Antimalarials, Malaria Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bill and Melinda Gates Foundation, Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

RTS,S/AS01 vaccine efficacy (VE) was previously shown as lower in African adults than in malaria-naive US adults, potentially due to concurrent Plasmodium falciparum infections. We investigated whether treatment of infection prior to vaccination would lead to improved VE and immunogenicity.

Methods

A phase 2b study in Kenyan adults evaluated the efficacy of RTS,S/AS01E in conjunction with antimalarial chemopreventive drugs. Participants, grouped by baseline presence or absence of P. falciparum infections, were randomized to receive RTS,S/AS01E or rabies vaccine. Four groups received antimalarial drugs prior to immunization and were followed for 6 months to assess P. falciparum infection. We included an additional group not treated with antimalarial drugs for immunological assessment.

Results

VE (RTS,S/AS01E vs rabies vaccine) was 34.8% (95% confidence interval [CI], 8.9% to 53.4%) and −24.0% (95% CI, −97% to 22.4%) in baseline P. falciparum-positive and P. falciparum-negative participants, respectively. In RTS,S/AS01E recipients, there were no statistical differences in anticircumsporozoite (anti-CS) antibody titers in baseline P. falciparum-positive or P. falciparum-negative participants, or in susceptibility to infection during the postvaccination follow-up period. Drug treatment did not improve anti-CS antibody titers.

Conclusions

Treating P. falciparum infections during vaccination does not result in increased VE. Anti-CS antibody responses to vaccination do not differ with baseline P. falciparum infection status, drug treatment, or susceptibility to P. falciparum infections. Clinical Trials Registration NCT04661579; PACTR202006896481432.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, FalciparumPlasmodium falciparumAntimalarialsMalaria VaccinesVaccine EfficacyParasitemiaHumansKenyaAdultMaleFemaleYoung AdultAntibodies, ProtozoanMiddle AgedAdolescentRabies VaccinesVaccines, Synthetic

Stichwörter der Autor:innen

CSP antibody titers and infectionRTS,S/AS01antimalarial drug treatment and malaria vaccinemalaria vaccine in African adultsvaccine-induced antibodies and infection

Substanzen

AntimalarialsMalaria VaccinesAntibodies, ProtozoanRTS,S-AS01 vaccineRabies VaccinesVaccines, Synthetic

Autor:innen und Institutionen

  • Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya.
  • Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland.
  • Biologics Research & Development, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Human Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
  • Vaccine Clinical R&D, GlaxoSmithKline, Wavre, Belgium.

ORCID-Profile: Nathanial K Copeland, Ben Andagalu, Emily Locke, Elke S Bergmann-Leitner, Mike Raine, Chris Gast, John J Aponte

Förderung

  • Bill and Melinda Gates Foundation
  • Gates Foundation

Zitieren

APA

Copeland, N. K., Otieno, L., Otieno, J. D., Otieno, S., Chira, S., Ivinson, K., Onyango, I., Wasuna, R., Akala, H., Onditi, A., Sifuna, P., Andagalu, B., Oyugi, R., Omondi, M., Amoit, S., Locke, E., Gregory, S., Bergmann-Leitner, E. S., Pindolia, H., …, & Lee, C. K. (2025). Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum -Exposed, Drug-Treated Kenyan Adults. The Journal of Infectious Diseases, 232(3), e372-e382. https://doi.org/10.1093/infdis/jiaf274

Vancouver

Copeland NK, Otieno L, Otieno JD, Otieno S, Chira S, Ivinson K, et al. Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum -Exposed, Drug-Treated Kenyan Adults. The Journal of Infectious Diseases. 2025;232(3):e372-e382. doi:10.1093/infdis/jiaf274

BibTeX
@article{Copeland2025,
  author = {Copeland, Nathanial K and Otieno, Lucas and Otieno, June Doryne and Otieno, Solomon and Chira, Salome and Ivinson, Karen and Onyango, Irene and Wasuna, Ruth and Akala, Hoseah and Onditi, Amos and Sifuna, Peter and Andagalu, Ben and Oyugi, Roselyne and Omondi, Mary and Amoit, Stellah and Locke, Emily and Gregory, Scott and Bergmann-Leitner, Elke S and Pindolia, Hema and Raine, Mike and Gast, Chris and Mercer, Laina D and Aponte, John J and Lievens, Marc and Ockenhouse, Christian F and Lee, Cynthia K},
  title = {Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum -Exposed, Drug-Treated Kenyan Adults},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {232},
  number = {3},
  pages = {e372--e382},
  doi = {10.1093/infdis/jiaf274}
}
Kostenlos starten →